<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02036775</url>
  </required_header>
  <id_info>
    <org_study_id>18.510</org_study_id>
    <nct_id>NCT02036775</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Bioavailability Study of Lasolvan Hard Capsules and Effervescent Tablets in Healthy Volunteers</brief_title>
  <official_title>An Open-label, Randomised, Multiple-dose, Three-period Crossover Study in Healthy Male and Female Volunteers to Characterise Pharmacokinetics and Assess the Relative Bioavailability of Two New Oral Formulations of Ambroxol Hydrochloride as Lasolvan® Prolonged-release Hard Capsules 75 mg and Lasolvan® Effervescent Tablets 60 mg Compared to Lasolvan® Tablets 30 mg.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To characterise pharmacokinetics and assess the relative bioavailability of two new oral
      formulations of ambroxol hydrochloride as Lasolvan® prolonged-release hard capsules 75 mg and
      Lasolvan® effervescent tablets 60 mg compared to Lasolvan® tablets 30 mg
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 24 h at Steady State</measure>
    <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24 h at steady state (AUCss 0-24)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Measured Concentration of the Analyte in Plasma at Steady State</measure>
    <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
    <description>Maximum measured concentration of the analyte in plasma at steady state (Cmax ss)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State During 0-24 h, Adjusted to a Daily Dose of 60 mg</measure>
    <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma at steady state during 0-24 h, adjusted to a daily dose of 60 mg (AUCss 0-24 norm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Absorption at Steady State (Cmax ss/AUCss 0-24)</measure>
    <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
    <description>Metric which characterises the rate of absorption at steady state (Cmax ss/AUCss 0-24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady State Concentration of the Analyte in Plasma at the End of Dosing Interval</measure>
    <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
    <description>Steady state concentration of the analyte in plasma at the end of dosing interval (Cmin ss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Concentration of the Analyte in Plasma in the Time Interval of 0 to 24 h at Steady State</measure>
    <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
    <description>Average concentration of the analyte in plasma in the time interval of 0 to 24 h at steady state (Cav ss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Dosing to the Maximum Concentration of the Analyte in Plasma at Steady State</measure>
    <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
    <description>Time from dosing to the maximum concentration of the analyte in plasma at steady state (tmax ss). For Lasolvan 30mg and Lasolvan 60mg, tmax ss was determined as tmax ss 0-12 and tmax ss 12-24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak-trough Fluctuation Between Minimum and Maximum Concentration of the Analyte in Plasma</measure>
    <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
    <description>Peak-trough fluctuation between minimum and maximum concentration of the analyte in plasma (PTF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak-trough Swing</measure>
    <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
    <description>Peak-trough swing (PTS) calculated as ((Cmax,ss - Cmin,ss / Cav,ss)*100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Period When Concentration of the Analyte Exceeds Cav ss</measure>
    <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
    <description>Time period when the concentration of the analyte exceeds Cav ss (T (C&gt;Cav ss))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plateau Time During Which Concentration of the Analyte in Plasma Exceeds 75% of Cmax ss</measure>
    <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
    <description>Plateau time during which concentration of the analyte in plasma exceeds 75% of Cmax ss (T(C&gt;75% Cmax ss))</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 1, Washout 6 days, Reference product, Washout 6 days, Treatment 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 2, Washout period 6 days, Treatment 1, Washout 6 days, Reference product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reference product, Washout 6 days, Treatment 2, Washout 6 days, Treatment 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 2, Washout 6 days, Reference product, Washout 6 days, Treatment 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reference product, Washout 6 days, Treatment 1, Washout 6 days, Treatment 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 1, Washout 6 days, Treatment 2, Washout 6 days, Reference product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasolvan tablet</intervention_name>
    <description>One Lasolvan tablet 30 mg twice daily for 5 days.</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasolvan tablet</intervention_name>
    <description>One Lasolvan tablet 30 mg twice daily for 5 days.</description>
    <arm_group_label>Treatment sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasolvan tablet</intervention_name>
    <description>One Lasolvan tablet 30 mg twice daily for 5 days.</description>
    <arm_group_label>Treatment Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasolvan tablet</intervention_name>
    <description>One Lasolvan tablet 30 mg twice daily for 5 days.</description>
    <arm_group_label>Treatment Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasolvan effervescent tablet</intervention_name>
    <description>One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.</description>
    <arm_group_label>Treatment sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasolvan effervescent tablet</intervention_name>
    <description>One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.</description>
    <arm_group_label>Treatment Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasolvan effervescent tablet</intervention_name>
    <description>One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.</description>
    <arm_group_label>Treatment Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasolvan prolonged-release hard capsule</intervention_name>
    <description>One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days</description>
    <arm_group_label>Treatment Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasolvan prolonged-release hard capsule</intervention_name>
    <description>One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days</description>
    <arm_group_label>Treatment Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasolvan prolonged-released capsules</intervention_name>
    <description>One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasolvan tablet</intervention_name>
    <description>One Lasolvan tablet 30 mg twice daily for 5 days.</description>
    <arm_group_label>Treatment sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasolvan tablet</intervention_name>
    <description>One Lasolvan tablet 30 mg twice daily for 5 days.</description>
    <arm_group_label>Treatment sequence 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasolvan prolonged-release hard capsule</intervention_name>
    <description>One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days</description>
    <arm_group_label>Treatment sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasolvan effervescent tablet</intervention_name>
    <description>One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.</description>
    <arm_group_label>Treatment sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasolvan prolonged-release hard capsule</intervention_name>
    <description>One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days</description>
    <arm_group_label>Treatment sequence 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasolvan prolonged-release hard capsule</intervention_name>
    <description>One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days</description>
    <arm_group_label>Treatment sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasolvan effervescent tablet</intervention_name>
    <description>One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.</description>
    <arm_group_label>Treatment sequence 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasolvan effervescent tablet</intervention_name>
    <description>One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Given written informed consent for participation in the study.

          -  Male and female subjects aged 18-45, inclusive.

          -  Body mass index by Quetelet 18.50 - 24.99 kg/m2, inclusive.

          -  Judged by the investigator to be in good health as documented by the medical history,
             physical examination (including but may not be limited to an evaluation of the
             cardiovascular, gastrointestinal, and renal systems), vital signs assessments, 12-lead
             electrocardiogram (ECG), clinical laboratory assessments, and by general observations.
             Any abnormalities outside normal ranges for any clinical testing (laboratory tests,
             ECG, vital signs) can be repeated at the discretion of the investigator and judged to
             be not clinically significant for the study participation.

          -  Female subjects of childbearing potential who agree on using double-barrier
             contraception during the study. If female is postmenopausal (no menses for at least 1
             year) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
             hysterectomy) she will be exempt from the requirement. In case of using oral
             contraceptives, they should be withdrawn at least 2 months before the study.

          -  Male subjects who agree on using effective contraception during the study (barrier
             contraceptive methods).

        Exclusion criteria:

          -  Known hypersensitivity to ambroxol hydrochloride, or other constituents of the test
             and reference products.

          -  Known rare hereditary conditions (Stevens-Johnson syndrome, toxic epidermal
             necrolysis, galactose intolerance, Lapp-lactase deficiency, glucose-galactose
             malabsorption).

          -  Pregnancy or breastfeeding.

          -  Chronic hepatic, renal, cardiovascular, respiratory, gastrointestinal, neuroendocrine
             diseases and blood disorders.

          -  Positive results of blood tests for current infections (HIV, syphilis, hepatitis B or
             C).

          -  Surgery of gastro-intestinal tract (except of appendectomy) within the past 8 weeks.

          -  Acute infections occurred within 4 weeks before inclusion into the study.

          -  Regular drug intake within 2 weeks before inclusion into the study.

          -  Intake of systemic drugs known to affect cytochrome P450 system (induce or inhibit)
             within 4 weeks before inclusion into the study.

          -  Blood donation (greater or equal 450 ml) within 2 months before inclusion into the
             study.

          -  Alcohol intake greater than or equal to 10 units of alcohol per week (1 unit of
             alcohol equals one 50 ml single measure of whisky (ABV - alcohol by volume 40%), or
             0.5 litre of beer (ABV 5%), or 200 ml glass of red wine (ABV 12%) or history of
             alcohol abuse, narcomania, or other drug abuse.

          -  A positive urine drug test (cannabis, benzodiazepines, barbiturates, opiates, cocaine,
             amphetamines) at screening and before the first dosing in each study period.

          -  A positive alcohol test at screening and before the first dosing in each study period

          -  Participation in another phase I clinical study within 3 months before inclusion into
             the study.

          -  Known lactose intolerance.

          -  Known phenylketonuria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>18.510.2 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2014</study_first_submitted>
  <study_first_submitted_qc>January 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2014</study_first_posted>
  <results_first_submitted>April 17, 2015</results_first_submitted>
  <results_first_submitted_qc>May 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 13, 2015</results_first_posted>
  <last_update_submitted>May 12, 2015</last_update_submitted>
  <last_update_submitted_qc>May 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ambroxol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A randomised, open-label, three period, crossover study. Each subject received one treatment per treatment period. Each of the three treatment phases was 6 days long, where study drug was administered on day 1-5 during each treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lasolvan 75mg / Lasolvan 30mg / Lasolvan 60mg</title>
          <description>Patients were administered three treatments in the following order:
One Lasolvan prolonged release hard capsule, 75mg, swallowed and taken with 200ml of boiled water once daily for 5 days
One Lasolvan tablet, 30mg, was taken with 200mL of boiled water twice daily for 5 days (reference treatment)
One-half Lasolvan effervescent tablet, 60mg, dissolved in 200mL of boiled water, taken twice daily for 5 days</description>
        </group>
        <group group_id="P2">
          <title>Lasolvan 60mg / Lasolvan 75mg / Lasolvan 30mg</title>
          <description>Patients were administered three treatments in the following order:
One-half Lasolvan effervescent tablet, 60mg, dissolved in 200mL of boiled water, taken twice daily for 5 days
One Lasolvan prolonged release hard capsule, 75mg, swallowed and taken with 200ml of boiled water once daily for 5 days
One Lasolvan tablet, 30mg, was taken with 200mL of boiled water twice daily for 5 days (reference treatment)</description>
        </group>
        <group group_id="P3">
          <title>Lasolvan 30mg / Lasolvan 60mg / Lasolvan 75mg</title>
          <description>Patients were administered three treatments in the following order:
One Lasolvan tablet, 30mg, was taken with 200mL of boiled water twice daily for 5 days (reference treatment)
One-half Lasolvan effervescent tablet, 60mg, dissolved in 200mL of boiled water, taken twice daily for 5 days
One Lasolvan prolonged release hard capsule, 75mg, swallowed and taken with 200ml of boiled water once daily for 5 days</description>
        </group>
        <group group_id="P4">
          <title>Lasolvan 60mg / Lasolvan 30mg / Lasolvan 75mg</title>
          <description>Patients were administered three treatments in the following order:
One-half Lasolvan effervescent tablet, 60mg, dissolved in 200mL of boiled water, taken twice daily for 5 days
One Lasolvan tablet, 30mg, was taken with 200mL of boiled water twice daily for 5 days (reference treatment)
One Lasolvan prolonged release hard capsule, 75mg, swallowed and taken with 200ml of boiled water once daily for 5 days</description>
        </group>
        <group group_id="P5">
          <title>Lasolvan 30mg / Lasolvan 75mg / Lasolvan 60mg</title>
          <description>Patients were administered three treatments in the following order:
One Lasolvan tablet, 30mg, was taken with 200mL of boiled water twice daily for 5 days (reference treatment)
One Lasolvan prolonged release hard capsule, 75mg, swallowed and taken with 200ml of boiled water once daily for 5 days
One-half Lasolvan effervescent tablet, 60mg, dissolved in 200mL of boiled water, taken twice daily for 5 days</description>
        </group>
        <group group_id="P6">
          <title>Lasolvan 75mg / Lasolvan 60mg / Lasolvan 30mg</title>
          <description>Patients were administered three treatments in the following order:
One Lasolvan prolonged release hard capsule, 75mg, swallowed and taken with 200ml of boiled water once daily for 5 days
One-half Lasolvan effervescent tablet, 60mg, dissolved in 200mL of boiled water, taken twice daily for 5 days
One Lasolvan tablet, 30mg, was taken with 200mL of boiled water twice daily for 5 days (reference treatment)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1 (6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2 (6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 3 (6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set which included all subjects who had been dispensed study medication and were documented to have taken at least one dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Study Overall</title>
          <description>A randomised, open-label, three period, crossover study. The three treatments administered were:
One Lasolvan prolonged release hard capsule, 75mg, swallowed and taken with 200ml of boiled water once daily for 5 days
One-half Lasolvan effervescent tablet, 60mg, dissolved in 200mL of boiled water, taken twice daily for 5 days
One Lasolvan tablet, 30mg, was taken with 200mL of boiled water twice daily for 5 days (reference treatment)
Each subject received one treatment per treatment period. Each of the three treatment phases was 6 days long, where study drug was administered on day 1-5 during each treatment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.04" spread="6.423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 24 h at Steady State</title>
        <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24 h at steady state (AUCss 0-24)</description>
        <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
        <population>Pharmacokinetic (PK) set relative bioavailability set (PK-BA set) which includes all subjects in the treated set who completed 3 periods and for whom the PK profiles in 3 periods could be adequately characterized in respect to at least 1 of the PK parameters of primary interest without important protocol violations relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Lasolvan 75mg</title>
            <description>One Lasolvan prolonged release hard capsule, 75mg, swallowed and taken with 200ml of boiled water once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Lasolvan 60mg</title>
            <description>One-half Lasolvan effervescent tablet, 60mg, dissolved in 200mL of boiled water, taken twice daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Lasolvan 30mg</title>
            <description>One Lasolvan tablet, 30mg, was taken with 200mL of boiled water twice daily for 5 days (reference treatment)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 24 h at Steady State</title>
          <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24 h at steady state (AUCss 0-24)</description>
          <population>Pharmacokinetic (PK) set relative bioavailability set (PK-BA set) which includes all subjects in the treated set who completed 3 periods and for whom the PK profiles in 3 periods could be adequately characterized in respect to at least 1 of the PK parameters of primary interest without important protocol violations relevant to the evaluation of PK.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1182.084" spread="28.859"/>
                    <measurement group_id="O2" value="1110.095" spread="28.292"/>
                    <measurement group_id="O3" value="1070.909" spread="32.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of relative bioavailability without molar mass adjustment (dose adjustment) was based upon two-sided 90% confidence intervals (CIs) for the ratios of the geometric means (test divided by reference) of the area under the curve (AUCss 0-24) using an acceptance range of 80%-125%.</non_inferiority_desc>
            <param_type>Adjusted Geometric Mean Ratio (%)</param_type>
            <param_value>110.68</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>20.42</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.84</ci_lower_limit>
            <ci_upper_limit>122.69</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the intra-individual geometric coefficient of variation (gCV(%))</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of relative bioavailability without molar mass adjustment (dose adjustment) was based upon two-sided 90% confidence intervals (CIs) for the ratios of the geometric means (test divided by reference) of the area under the curve (AUCss 0-24) using an acceptance range of 80%-125%.</non_inferiority_desc>
            <param_type>Adjusted Geometric Mean Ratio (%)</param_type>
            <param_value>103.39</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>13.52</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.54</ci_lower_limit>
            <ci_upper_limit>110.74</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the intra-individual geometric coefficient of variation (gCV(%))</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of relative bioavailability without molar mass adjustment (dose adjustment) was based upon two-sided 90% confidence intervals (CIs) for the ratios of the geometric means (test divided by reference) of the area under the curve (AUCss 0-24) using an acceptance range of 80%-125%.</non_inferiority_desc>
            <param_type>Adjusted Geometric Mean Ratio (%)</param_type>
            <param_value>106.93</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12.65</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>100.29</ci_lower_limit>
            <ci_upper_limit>114.02</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the intra-individual geometric coefficient of variation (gCV(%))</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Measured Concentration of the Analyte in Plasma at Steady State</title>
        <description>Maximum measured concentration of the analyte in plasma at steady state (Cmax ss)</description>
        <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
        <population>PK-BA set</population>
        <group_list>
          <group group_id="O1">
            <title>Lasolvan 75mg</title>
            <description>One Lasolvan prolonged release hard capsule, 75mg, swallowed and taken with 200ml of boiled water once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Lasolvan 60mg</title>
            <description>One-half Lasolvan effervescent tablet, 60mg, dissolved in 200mL of boiled water, taken twice daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Lasolvan 30mg</title>
            <description>One Lasolvan tablet, 30mg, was taken with 200mL of boiled water twice daily for 5 days (reference treatment)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Measured Concentration of the Analyte in Plasma at Steady State</title>
          <description>Maximum measured concentration of the analyte in plasma at steady state (Cmax ss)</description>
          <population>PK-BA set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.510" spread="26.927"/>
                    <measurement group_id="O2" value="90.755" spread="34.426"/>
                    <measurement group_id="O3" value="87.289" spread="34.426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of relative bioavailability without molar mass adjustment (dose adjustment) was based upon two-sided 90% confidence intervals (CIs) for the ratios of the geometric means (test divided by reference) of the peak concentration (Cmax ss) using an acceptance range of 75%-133%.</non_inferiority_desc>
            <param_type>Adjusted Geometric Mean Ratio (%)</param_type>
            <param_value>84.72</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>19.01</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>76.96</ci_lower_limit>
            <ci_upper_limit>93.25</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the intra-individual geometric coefficient of variation (gCV(%))</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of relative bioavailability without molar mass adjustment (dose adjustment) was based upon two-sided 90% confidence intervals (CIs) for the ratios of the geometric means (test divided by reference) of the peak concentration (Cmax ss) using an acceptance range of 75%-133%.</non_inferiority_desc>
            <param_type>Adjusted Geometric Mean Ratio (%)</param_type>
            <param_value>103.87</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>17.19</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.22</ci_lower_limit>
            <ci_upper_limit>113.31</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the intra-individual geometric coefficient of variation (gCV(%))</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of relative bioavailability without molar mass adjustment (dose adjustment) was based upon two-sided 90% confidence intervals (CIs) for the ratios of the geometric means (test divided by reference) of the peak concentration (Cmax ss) using an acceptance range of 75%-133%.</non_inferiority_desc>
            <param_type>Adjusted Geometric Mean Ratio (%)</param_type>
            <param_value>80.94</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>17.95</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>73.92</ci_lower_limit>
            <ci_upper_limit>88.62</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the intra-individual geometric coefficient of variation (gCV(%))</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State During 0-24 h, Adjusted to a Daily Dose of 60 mg</title>
        <description>Area under the concentration-time curve of the analyte in plasma at steady state during 0-24 h, adjusted to a daily dose of 60 mg (AUCss 0-24 norm)</description>
        <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
        <population>PK-BA set</population>
        <group_list>
          <group group_id="O1">
            <title>Lasolvan 75mg</title>
            <description>One Lasolvan prolonged release hard capsule, 75mg, swallowed and taken with 200ml of boiled water once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Lasolvan 60mg</title>
            <description>One-half Lasolvan effervescent tablet, 60mg, dissolved in 200mL of boiled water, taken twice daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Lasolvan 30mg</title>
            <description>One Lasolvan tablet, 30mg, was taken with 200mL of boiled water twice daily for 5 days (reference treatment)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State During 0-24 h, Adjusted to a Daily Dose of 60 mg</title>
          <description>Area under the concentration-time curve of the analyte in plasma at steady state during 0-24 h, adjusted to a daily dose of 60 mg (AUCss 0-24 norm)</description>
          <population>PK-BA set</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="945.667" spread="28.859"/>
                    <measurement group_id="O2" value="1110.095" spread="28.292"/>
                    <measurement group_id="O3" value="1070.909" spread="32.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of relative bioavailability without molar mass adjustment (dose adjustment) was based upon two-sided 90% confidence intervals (CIs) for the ratios of the geometric means (test divided by reference) for the dose-adjusted total exposure (AUCss 0-24 norm) using an acceptance range of 80%-125%.</non_inferiority_desc>
            <param_type>Adjusted Geometric Mean Ratio (%)</param_type>
            <param_value>88.54</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>20.42</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>79.87</ci_lower_limit>
            <ci_upper_limit>98.15</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the intra-individual geometric coefficient of variation (gCV(%))</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of relative bioavailability without molar mass adjustment (dose adjustment) was based upon two-sided 90% confidence intervals (CIs) for the ratios of the geometric means (test divided by reference) for the dose-adjusted total exposure (AUCss 0-24 norm) using an acceptance range of 80%-125%.</non_inferiority_desc>
            <param_type>Adjusted Geometric Mean Ratio (%)</param_type>
            <param_value>103.39</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>13.52</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.54</ci_lower_limit>
            <ci_upper_limit>110.74</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the intra-individual geometric coefficient of variation (gCV(%))</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of relative bioavailability without molar mass adjustment (dose adjustment) was based upon two-sided 90% confidence intervals (CIs) for the ratios of the geometric means (test divided by reference) for the dose-adjusted total exposure (AUCss 0-24 norm) using an acceptance range of 80%-125%.</non_inferiority_desc>
            <param_type>Adjusted Geometric Mean Ratio (%)</param_type>
            <param_value>85.55</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12.65</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>80.23</ci_lower_limit>
            <ci_upper_limit>91.22</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the intra-individual geometric coefficient of variation (gCV(%))</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Absorption at Steady State (Cmax ss/AUCss 0-24)</title>
        <description>Metric which characterises the rate of absorption at steady state (Cmax ss/AUCss 0-24)</description>
        <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
        <population>PK-BA set</population>
        <group_list>
          <group group_id="O1">
            <title>Lasolvan 75mg</title>
            <description>One Lasolvan prolonged release hard capsule, 75mg, swallowed and taken with 200ml of boiled water once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Lasolvan 60mg</title>
            <description>One-half Lasolvan effervescent tablet, 60mg, dissolved in 200mL of boiled water, taken twice daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Lasolvan 30mg</title>
            <description>One Lasolvan tablet, 30mg, was taken with 200mL of boiled water twice daily for 5 days (reference treatment)</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Absorption at Steady State (Cmax ss/AUCss 0-24)</title>
          <description>Metric which characterises the rate of absorption at steady state (Cmax ss/AUCss 0-24)</description>
          <population>PK-BA set</population>
          <units>1/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.062" spread="13.477"/>
                    <measurement group_id="O2" value="0.082" spread="14.568"/>
                    <measurement group_id="O3" value="0.082" spread="13.477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of relative bioavailability without molar mass adjustment (dose adjustment) was based upon two-sided 90% confidence intervals (CIs) for the ratios of the geometric means (test divided by reference) for the rate of absorption at steady state (Cmax ss/AUCss 0-24) using an acceptance range of 75%-133%.</non_inferiority_desc>
            <param_type>Adjusted Geometric Mean Ratio (%)</param_type>
            <param_value>76.55</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.55</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>71.10</ci_lower_limit>
            <ci_upper_limit>82.40</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the intra-individual geometric coefficient of variation (gCV(%))</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of relative bioavailability without molar mass adjustment (dose adjustment) was based upon two-sided 90% confidence intervals (CIs) for the ratios of the geometric means (test divided by reference) for the rate of absorption at steady state (Cmax ss/AUCss 0-24) using an acceptance range of 75%-133%.</non_inferiority_desc>
            <param_type>Adjusted Geometric Mean Ratio (%)</param_type>
            <param_value>100.46</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.65</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.69</ci_lower_limit>
            <ci_upper_limit>106.58</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the intra-individual geometric coefficient of variation (gCV(%))</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of relative bioavailability without molar mass adjustment (dose adjustment) was based upon two-sided 90% confidence intervals (CIs) for the ratios of the geometric means (test divided by reference) for the rate of absorption at steady state (Cmax ss/AUCss 0-24) using an acceptance range of 75%-133%.</non_inferiority_desc>
            <param_type>Adjusted Geometric Mean Ratio (%)</param_type>
            <param_value>75.69</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>15.64</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>69.92</ci_lower_limit>
            <ci_upper_limit>81.93</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the intra-individual geometric coefficient of variation (gCV(%))</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steady State Concentration of the Analyte in Plasma at the End of Dosing Interval</title>
        <description>Steady state concentration of the analyte in plasma at the end of dosing interval (Cmin ss)</description>
        <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lasolvan 75mg</title>
            <description>One Lasolvan prolonged release hard capsule, 75mg, swallowed and taken with 200ml of boiled water once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Lasolvan 60mg</title>
            <description>One-half Lasolvan effervescent tablet, 60mg, dissolved in 200mL of boiled water, taken twice daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Lasolvan 30mg</title>
            <description>One Lasolvan tablet, 30mg, was taken with 200mL of boiled water twice daily for 5 days (reference treatment)</description>
          </group>
        </group_list>
        <measure>
          <title>Steady State Concentration of the Analyte in Plasma at the End of Dosing Interval</title>
          <description>Steady state concentration of the analyte in plasma at the end of dosing interval (Cmin ss)</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.891" spread="39.355"/>
                    <measurement group_id="O2" value="22.740" spread="37.260"/>
                    <measurement group_id="O3" value="21.523" spread="40.803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Concentration of the Analyte in Plasma in the Time Interval of 0 to 24 h at Steady State</title>
        <description>Average concentration of the analyte in plasma in the time interval of 0 to 24 h at steady state (Cav ss)</description>
        <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
        <population>PK-BA set</population>
        <group_list>
          <group group_id="O1">
            <title>Lasolvan 75mg</title>
            <description>One Lasolvan prolonged release hard capsule, 75mg, swallowed and taken with 200ml of boiled water once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Lasolvan 60mg</title>
            <description>One-half Lasolvan effervescent tablet, 60mg, dissolved in 200mL of boiled water, taken twice daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Lasolvan 30mg</title>
            <description>One Lasolvan tablet, 30mg, was taken with 200mL of boiled water twice daily for 5 days (reference treatment)</description>
          </group>
        </group_list>
        <measure>
          <title>Average Concentration of the Analyte in Plasma in the Time Interval of 0 to 24 h at Steady State</title>
          <description>Average concentration of the analyte in plasma in the time interval of 0 to 24 h at steady state (Cav ss)</description>
          <population>PK-BA set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.254" spread="28.859"/>
                    <measurement group_id="O2" value="46.254" spread="28.292"/>
                    <measurement group_id="O3" value="44.621" spread="32.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Dosing to the Maximum Concentration of the Analyte in Plasma at Steady State</title>
        <description>Time from dosing to the maximum concentration of the analyte in plasma at steady state (tmax ss). For Lasolvan 30mg and Lasolvan 60mg, tmax ss was determined as tmax ss 0-12 and tmax ss 12-24.</description>
        <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
        <population>PK-BA set</population>
        <group_list>
          <group group_id="O1">
            <title>Lasolvan 75mg</title>
            <description>One Lasolvan prolonged release hard capsule, 75mg, swallowed and taken with 200ml of boiled water once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Lasolvan 60mg</title>
            <description>One-half Lasolvan effervescent tablet, 60mg, dissolved in 200mL of boiled water, taken twice daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Lasolvan 30mg</title>
            <description>One Lasolvan tablet, 30mg, was taken with 200mL of boiled water twice daily for 5 days (reference treatment)</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Dosing to the Maximum Concentration of the Analyte in Plasma at Steady State</title>
          <description>Time from dosing to the maximum concentration of the analyte in plasma at steady state (tmax ss). For Lasolvan 30mg and Lasolvan 60mg, tmax ss was determined as tmax ss 0-12 and tmax ss 12-24.</description>
          <population>PK-BA set</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax,ss,0-12h (N=0, 23, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This was not determined for Lasolvan 75mg as dosing was once daily.</measurement>
                    <measurement group_id="O2" value="1.00" lower_limit="0.75" upper_limit="3.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="0.75" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax,ss,12-24h (N=0, 23, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This was not determined for Lasolvan 75mg as dosing was once daily.</measurement>
                    <measurement group_id="O2" value="13.50" lower_limit="12.75" upper_limit="16.00"/>
                    <measurement group_id="O3" value="14.00" lower_limit="13.00" upper_limit="16.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax,ss,h (N=23, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="2.00" upper_limit="12.00"/>
                    <measurement group_id="O2" value="NA">Tmax,ss was determined as tmax,ss 0-12 and tmax,ss 12-24 for Lasolvan 60mg as dosing was twice daily.</measurement>
                    <measurement group_id="O3" value="NA">Tmax,ss was determined as tmax,ss 0-12 and tmax,ss 12-24 for Lasolvan 30mg as dosing was twice daily</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak-trough Fluctuation Between Minimum and Maximum Concentration of the Analyte in Plasma</title>
        <description>Peak-trough fluctuation between minimum and maximum concentration of the analyte in plasma (PTF)</description>
        <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
        <population>PK-BA set</population>
        <group_list>
          <group group_id="O1">
            <title>Lasolvan 75mg</title>
            <description>One Lasolvan prolonged release hard capsule, 75mg, swallowed and taken with 200ml of boiled water once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Lasolvan 60mg</title>
            <description>One-half Lasolvan effervescent tablet, 60mg, dissolved in 200mL of boiled water, taken twice daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Lasolvan 30mg</title>
            <description>One Lasolvan tablet, 30mg, was taken with 200mL of boiled water twice daily for 5 days (reference treatment)</description>
          </group>
        </group_list>
        <measure>
          <title>Peak-trough Fluctuation Between Minimum and Maximum Concentration of the Analyte in Plasma</title>
          <description>Peak-trough fluctuation between minimum and maximum concentration of the analyte in plasma (PTF)</description>
          <population>PK-BA set</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.994" spread="0.278"/>
                    <measurement group_id="O2" value="1.482" spread="0.322"/>
                    <measurement group_id="O3" value="1.483" spread="0.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak-trough Swing</title>
        <description>Peak-trough swing (PTS) calculated as ((Cmax,ss - Cmin,ss / Cav,ss)*100)</description>
        <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
        <population>PK-BA set</population>
        <group_list>
          <group group_id="O1">
            <title>Lasolvan 75mg</title>
            <description>One Lasolvan prolonged release hard capsule, 75mg, swallowed and taken with 200ml of boiled water once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Lasolvan 60mg</title>
            <description>One-half Lasolvan effervescent tablet, 60mg, dissolved in 200mL of boiled water, taken twice daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Lasolvan 30mg</title>
            <description>One Lasolvan tablet, 30mg, was taken with 200mL of boiled water twice daily for 5 days (reference treatment)</description>
          </group>
        </group_list>
        <measure>
          <title>Peak-trough Swing</title>
          <description>Peak-trough swing (PTS) calculated as ((Cmax,ss - Cmin,ss / Cav,ss)*100)</description>
          <population>PK-BA set</population>
          <units>percentage of ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205.054" spread="82.703"/>
                    <measurement group_id="O2" value="313.106" spread="113.101"/>
                    <measurement group_id="O3" value="322.120" spread="135.222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Period When Concentration of the Analyte Exceeds Cav ss</title>
        <description>Time period when the concentration of the analyte exceeds Cav ss (T (C&gt;Cav ss))</description>
        <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
        <population>PK-BA set</population>
        <group_list>
          <group group_id="O1">
            <title>Lasolvan 75mg</title>
            <description>One Lasolvan prolonged release hard capsule, 75mg, swallowed and taken with 200ml of boiled water once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Lasolvan 60mg</title>
            <description>One-half Lasolvan effervescent tablet, 60mg, dissolved in 200mL of boiled water, taken twice daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Lasolvan 30mg</title>
            <description>One Lasolvan tablet, 30mg, was taken with 200mL of boiled water twice daily for 5 days (reference treatment)</description>
          </group>
        </group_list>
        <measure>
          <title>Time Period When Concentration of the Analyte Exceeds Cav ss</title>
          <description>Time period when the concentration of the analyte exceeds Cav ss (T (C&gt;Cav ss))</description>
          <population>PK-BA set</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.500" lower_limit="8.00" upper_limit="12.50"/>
                    <measurement group_id="O2" value="8.500" lower_limit="5.75" upper_limit="10.00"/>
                    <measurement group_id="O3" value="7.750" lower_limit="5.25" upper_limit="10.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plateau Time During Which Concentration of the Analyte in Plasma Exceeds 75% of Cmax ss</title>
        <description>Plateau time during which concentration of the analyte in plasma exceeds 75% of Cmax ss (T(C&gt;75% Cmax ss))</description>
        <time_frame>Pre-dose, 30min, 1h, 1h 30min, 2h, 3h, 4h, 5h, 6h, 7h 30min, 9h, 10h 30min, 12h, 14h, 17h, 20h, 24h after the morning dose for all treatments; also 15min, 45min, 12h 15min, 12h 30min, 12h 45min, 13h, 13h 30min, 15h, 16h for Lasolvan 60mg and Lasolvan 30mg</time_frame>
        <population>PK-BA set</population>
        <group_list>
          <group group_id="O1">
            <title>Lasolvan 75mg</title>
            <description>One Lasolvan prolonged release hard capsule, 75mg, swallowed and taken with 200ml of boiled water once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Lasolvan 60mg</title>
            <description>One-half Lasolvan effervescent tablet, 60mg, dissolved in 200mL of boiled water, taken twice daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Lasolvan 30mg</title>
            <description>One Lasolvan tablet, 30mg, was taken with 200mL of boiled water twice daily for 5 days (reference treatment)</description>
          </group>
        </group_list>
        <measure>
          <title>Plateau Time During Which Concentration of the Analyte in Plasma Exceeds 75% of Cmax ss</title>
          <description>Plateau time during which concentration of the analyte in plasma exceeds 75% of Cmax ss (T(C&gt;75% Cmax ss))</description>
          <population>PK-BA set</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" lower_limit="0.00" upper_limit="13.00"/>
                    <measurement group_id="O2" value="2.25" lower_limit="0.50" upper_limit="5.75"/>
                    <measurement group_id="O3" value="2.00" lower_limit="0.50" upper_limit="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From drug administration until the end of the consequent residual effect period (24 hours) for the treatment taken immediately before, 6 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lasolvan 75mg</title>
          <description>One Lasolvan prolonged release hard capsule, 75mg, swallowed and taken with 200ml of boiled water once daily for 5 days</description>
        </group>
        <group group_id="E2">
          <title>Lasolvan 60mg</title>
          <description>One-half Lasolvan effervescent tablet, 60mg, dissolved in 200mL of boiled water, taken twice daily for 5 days</description>
        </group>
        <group group_id="E3">
          <title>Lasolvan 30mg</title>
          <description>One Lasolvan tablet, 30mg, was taken with 200mL of boiled water twice daily for 5 days (reference treatment)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

